First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

Peters, S.Scherpereel, A.Cornelissen, R.Oulkhouir, Y.Greillier, L.Kaplan, M. A.Talbot, T.2024-04-242024-04-2420210923-75341569-8041https://doi.org/10.1016/j.annonc.2021.08.2146https://hdl.handle.net/11468/15130Congress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 16-21, 2021 -- ELECTR NETWORK[Abstract Not Available]eninfo:eu-repo/semantics/openAccess[No Keyword]First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743Conference Object32S1341S1342WOS:00070052770402510.1016/j.annonc.2021.08.2146Q1